Thanks for all your arduous work and taking the time to be part of s4me and explain all that complicated stuff.Thanks. The more tempered statement is only relevant to the DecodeME GWAS result ("chr6p associated locus" containing several genes, including BTN2A1). The AstraZeneca result is specific to the gene: BTN2A1 has the significantly highest odds of disruptive rare DNA variants among pwME relative to people who do not have ME/CFS.
Yes, these genetic associations could be conferring risk mostly through increased susceptibility to infection (acute phase) rather than mechanisms acting subsequently.
What I find interesting about BTN2A1 is that it acts in innate immunity. Together with BTN3A1 it is a first-line sensor of bacterial presence, and it mediates the interaction with Vgamma9-Vdelta2 T-cells, which are "innate-like" lymphocytes.
Could that mean having EBV and pneumonia as the starting point of ME/CFS is a double whammy?
Obvious that I'm the opposite of a scientist.